
Danish biotech company Genmab announces in a press release that the US Food and Drug Administration (FDA) has designated the company’s investigational drug, epcoritamab, an orphan drug.
Epcoritamab, which is being developed in a collaboration between Genmab and its partner Abbvie, is designed to treat follicular lymphoma (FL), a type of cancer that forms in the lymphatic system.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app